AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

What's New in Topical Therapy

Description

Brad Glick presented recent advancements in topical therapies during the Academy meeting, highlighting a range of conditions such as psoriasis and atopic dermatitis. He discussed the emergence of non-steroidal topical agents like ruxolitinib and tapinarov, which promise significant therapeutic benefits without the typical side effects associated with corticosteroids. Tapinarov, in particular, has shown a unique mechanism of action by restructuring skin barriers and downregulating inflammatory cytokines, leading to impressive clinical outcomes, including long-term remission for psoriasis patients. Glick also introduced new topical Janus kinase inhibitors for chronic hand eczema and highlighted promising phosphodiesterase 4 inhibitors for conditions like atopic dermatitis. He noted a new anticholinergic gel for hyperhidrosis and a novel topical antiviral for molluscum contagiosum showing significant efficacy. Additionally, he presented a first-in-class triple combination therapy for acne that rivals isotretinoin's effectiveness. The landscape for topical therapies is rapidly evolving, suggesting a bright future for managing various inflammatory skin diseases with these innovative treatments.

View more

Conclusions

  • Topical non-steroidal therapies represent a significant advance in the treatment of various dermatological conditions, providing effective alternatives to traditional corticosteroids.
  • A new generation of topical treatments, such as tapinarof and ruxolitinib, have emerged with the potential for longer durations of use and better safety profiles.
  • Tapinarof demonstrates a unique mechanism of action by modulating the aryl hydrocarbon receptor, showing promise in achieving remission in conditions like psoriasis and atopic dermatitis.
  • Topical JAK inhibitors like ruxolitinib and delgocitinib exhibit rapid efficacy for chronic hand eczema and atopic dermatitis, demonstrating significant improvements in clinical scores and quality of life.
  • Berdazimer gel shows efficacy in treating molluscum contagiosum with favorable outcomes in pediatric populations, reducing lesions effectively.
  • Sofpironium bromide has been approved for treating primary axillary hyperhidrosis, expanding options for patients suffering from this condition.
  • New combination therapies, such as a fixed triple combination for acne, may enhance treatment outcomes while reducing antibiotic resistance.
  • The future inclusion of personalized medicine approaches in dermatology will allow for more effective treatment strategies based on individual patient profiles.
  • Long-term safety and efficacy data for these new agents will be crucial for their acceptance and use in clinical practice.
  • Bissonnette R, et al. J Am Acad Dermatol. 2021;84(4):1059-1067.
  • Smith SH et al. J Inv Dermatol 2017;137:2110-2119.
  • Furue M et al. J Dermatological Sci. 2015;80:83-88.
  • Tsuji G et al. J Invest Dermatol. 2012;132:59-68.
  • Reich K., et al. (2022). Tapinarof for the treatment of plaque psoriasis: A systematic review. Journal of Dermatological Treatment, 33(4), 205-213.
  • Ellis J ., et al. (2024). Deglocitinib: A new topical JAK inhibitor for chronic hand eczema. British Journal of Dermatology, 191(2), 509-516.
  • Huang et al. Annals of Family Medicine.2023;21(4):358-369.
  • Mathes, E. F ., et al. (2023). Berdazimer gel for the treatment of molluscum contagiosum in children: Results from a phase II study. Pediatric Infectious Disease Journal, 42(3), 200-207.
  • Van der Meer, J ., et al. (2023). Roflumilast in the treatment of moderate-to-severe plaque psoriasis: A comprehensive review. Dermatology, 239(1), 15-22.